Randomized, Double-blind, Placebo-controlled Phase 2B Study on Safety and Therapeutic Efficacy of DAS181 in Adult Subjects With Naturally Acquired Influenza.
Latest Information Update: 09 Jul 2019
Price :
$35 *
At a glance
- Drugs Oplunofusp (Primary)
- Indications Influenza virus infections
- Focus Adverse reactions
- Sponsors Ansun Biopharma
- 03 Jul 2019 Status changed from active, no longer recruiting to completed.
- 11 Jul 2013 Status changed from not yet recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 08 Jan 2013 New trial record